tbuckley/cabot-search huggingface dataset:
Systematic review and meta-analysis on fully automated digital cognitive behavioral therapy for insomnia
Authors: Ji Woo Hwang, Ga Eun Lee, Jae Hyun Woo, Sung Min Kim, Ji Yean Kwon
Journal: npj Digital Medicine (2025)

Insomnia impairs daily functioning and increases health risks. Cognitive behavioral therapy for insomnia (CBT-I) is effective but limited by cost and therapist availability. Fully automated digital CBT-I (FA dCBT-I) provides an accessible alternative without therapist involvement. This systematic review and meta-analysis evaluated the effectiveness of FA dCBT-I across 29 randomized controlled trials (RCTs) involving 9475 participants. Compared to control groups, FA dCBT-I demonstrated moderate to large effects on insomnia severity. Subgroup analyses indicated that FA dCBT-I had a significant impact when contrasted with most control groups but was less effective than therapist-assisted CBT-I. Meta-regression revealed that control group type moderated outcomes, whereas completion rate did not. This implies that treatment adherence, rather than merely completing the intervention, is crucial for its effectiveness. This study supports the potential of FA dCBT-I as a promising option for managing insomnia but underscores that a hybrid model combining therapist support is more beneficial.
Long term latency of highly mutated cells in normal mouse skin is reversed by exposure to tumor promoters and chronic tissue damage.
Authors: Yun Rose. Li, Eve Kandyba, Kyle Halliwill, Reyno Delrosario, Quan Tran, Nora Bayani, Di Wu, Olga K. Mirzoeva, Melissa Quino. Reeves, S M Ashiqul Islam, Laura Riva, Erik N. Bergstrom, Kavya Achanta, John DiGiovanni, Ludmil B. Alexandrov, Allan Balmain
Journal: Cancer Discovery (2025)

Abstract Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell proliferation. Initiation was proposed to be permanent, with promotion as the critical rate-limiting step for cancer development. Here, we carried out whole genome sequencing to demonstrate that initiated cells with thousands of mutagen-induced mutations can persist for long periods and are not removed by cell competition or by immune intervention, thus mimicking the persistence of cells with cancer driver mutations in normal human tissues. In the mouse, these cells do not give rise to tumors unless exposed to the tumor promoter TPA. Tissue damage and regenerative proliferation, but not normal cell turnover, consistently trigger tumor formation. Wounding, promoter treatment, and obesity enhance promotion without increasing mutational burden, supporting the possibility of future cancer prevention efforts directed at promotional risk factors.
Endoscopic removal of intrahepatic bile duct stones using a slim basket catheter passed through a device delivery system in a patient who had undergone pancreaticoduodenectomy
Authors: Yuichi Hirata, Kazuhiro Iida, Kei Takahashi, Daisuke Orita, Yoshihiro Okabe
Journal: Endoscopy (2025)

Endoscopic removal of intrahepatic bile duct (IHBD) stones is often challenging in patients who have undergone pancreaticoduodenectomy [1], especially in the right IHBD, where device insertion is complicated by the acute angle between the endoscope and the bile duct. Endoscopic removal of IHBD stones using conventional stone retrieval baskets is sometimes difficult, and reports on suitably improved devices are limited [2]. Herein, we report the case of a patient who had undergone pancreaticoduodenectomy in whom a slim basket catheter was passed through a device delivery system and used for endoscopic removal of right IHBD stones.
mRNA m6A regulates gene expression via H3K4me3 shift in 5’ UTR
Authors: Yuna Yang, Yuqing Huang, Tian Wang, Song Li, Jiafu Jiang, Sumei Chen, Fadi Chen, Likai Wang
Journal: Genome biology (2025)

Abstract Background N 6 -methyladenosine (m 6 A) is a prevalent and conserved RNA modification in eukaryotes. While its roles in the 3’ untranslated regions (3’ UTR) are well-studied, its role in the 5' UTR and its relationship with histone modifications remain underexplored. Results We demonstrate that m 6 A methylation in the 5’ UTR of mRNA triggers a downstream shift in H3K4me3 modification. This regulatory mechanism is conserved in Arabidopsis , rice, and chrysanthemum. The observed shift in H3K4me3 is genetically controlled by m 6 A modifiers and influences gene expression. MTA, the m 6 A methylase, preferentially binds to phosphorylated serine 5 (Ser5P)-CTD of RNA Pol II during transcription, leading to the displacement of ATX1, the H3K4me3 methylase. This dynamic binding of MTA and ATX1 to RNA Pol II ultimately results in the shift of H3K4me3 modification. Genetic evidence demonstrates that m 6 A in the 5' UTR controls H3K4me3 shift, thereby affecting SEDOHEPTULOSE-BISPHOSPHATASE expression and leaf senescence. Conclusions Our study provides new insights into the roles of m 6 A modification and its crosstalk with histone modification in 5’ UTRs, shedding light on the mechanism of m 6 A-mediated gene expression regulation.
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
Authors: Seok Jin Kim, Jing Quan Lim, Sang Eun Yoon, Deok-Hwan Yang, Ji Hyun Lee, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung-Nam Lim, Junhun Cho, Bon Park, Kyung Ju Ryu, Seunghyun Choi, Yoon Park, Kerry May Huifen Lim, Nur Ayuni Binte Muhammad Taib, Choon Kiat Ong, Soon Thye Lim, Won Seog Kim
Journal: Blood (2025)
A Controlled Trial for Preventing Priapism in Sickle Cell Anemia: Hydroxyurea plus Placebo vs Hydroxyurea plus Tadalafil
Authors: Ibrahim Musa Idris, Aminu Abba Yusuf, Ismail Isah Ismail, Awwal Musa Borodo, Mustapha Shuaibu Hikima, Shehu Abubakar Kana, Tukur Aliyu, Kabiru Musan Gedu, Atiku Usman Jibrillah, Sani Ali Aji, Aisha Kuliya-Gwarzo, Kabeer Bello Mohammed, Jamil A . Galadanci, Rukayya Sunusi Alkassim, Mohammad Abba Suwaid, Nafiu Hussaini, Mark Rodeghier, Arthur Louis Burnett, Michael R DeBaun
Journal: Blood (2025)
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+
Authors: Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, Junko Tsuji, Jean-Baptiste Alberge, Michelle P Aranha, Daniel Lewis Heilpern-Mallory, Harvey G. Roweth, Daisy Huyng, Stephen Jun Fei Chong, Anna Y. Chung, Jeremy Zhang, Liam Hackett, Nicholas J Haradhvala, Ting Wu, Nang Kham Su, Brianna Berrios, Saveliy Belkin, Ankit K. Dutta, Ryan A Knudson, Carolyn Brandt, Patricia T. Greipp, Matthew S. Davids, Maria Papaioannou, Gad Getz, Irene M Ghobrial, Salomon Manier
Journal: Blood (2025)
Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study
Authors: Caroline Boman, Christian Tranchell, Xingrong Liu, Louise Eriksson Bergman, Maria Angeliki Toli, Jonas Bergh, Theodoros Foukakis, Alexios Matikas
Journal: Journal of the National Comprehensive Cancer Network (2025)

Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) for early-stage breast cancer is prognostic, but not the sole surrogate marker for long-term outcome at a trial level, given that recurrence risk persists in patients who achieve pCR. This study aimed to investigate factors affecting the outcome of patients who achieve pCR. Methods: This population-based cohort study prospectively enrolled patients who received NACT for nonmetastatic breast cancer between 2007 and 2020 in the Stockholm-Gotland region, which comprises 25% of the entire Swedish population. The primary endpoint was distant relapse-free survival (DRFS), defined as time from surgery to distant recurrence or death from any cause. Results: Median follow-up from surgery was 5.9 years. Among 2,487 patients, 661 (26.6%) attained pCR. Several factors were independently associated with DRFS in patients with pCR, including increasing age (adjusted hazard ratio [aHR], 1.04; 95% CI, 1.01–1.06), T3/T4 stage (aHR, 2.02; 95% CI, 1.05–3.87), and HER2 positivity (aHR, 0.34; 95% CI, 0.17–0.68). Node positivity predicted distant recurrence during the first year postsurgery (aHR, 2.84; 95% CI, 1.16–6.94), whereas estrogen receptor positivity predicted distant recurrence at 5 to 10 years (aHR, 4.30; 95% CI, 1.06–17.49). The rate of central nervous system relapse as the first site of recurrence was not affected by pCR status (5.3% vs 4.1%; P =.21). Conclusions: In this population-based study, our findings suggest that patients achieving pCR after NACT are a heterogeneous group in terms of long-term prognosis. Baseline tumor characteristics should be considered when investigating post-neoadjuvant therapy approaches.
Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients
Authors: Patric Karlström, Aldina Pivodic, Michael Fu
Journal: JACC Heart Failure (2025)

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown improved symptomatic relieving and functional capacity in patients with heart failure (HF) with preserved ejection fraction and obesity. The purpose of this study was to evaluate the effect of GLP-1RA on outcome in patients with HF. A retrospective analysis was performed based on the Swedish HF Registry since 2007 among patients with a body mass index (BMI) >25 kg/m2 to assess whether GLP-1RA treatment was associated with reduced mortality in patients with HF. In the overall cohort, 34,247 patients were not treated with GLP-1RA, and 808 patients were. In patients treated with GLP-1RA, 96.3% had diabetes mellitus. Treatment with GLP-1RA showed a statistically significant association with reduced all-cause (adjusted HR [aHR]: 0.75 [95% CI: 0.60-0.94]; P = 0.013) and cardiovascular (CV) mortality (aHR: 0.52 [95% CI: 0.35-0.77]; P = 0.0010) compared with those not receiving GLP-1RA within 2 years after index registration. In a 1:1 propensity score matched cohort, there was no significant association between GLP-1RA and all-cause mortality (aHR: 0.79 [95% CI: 0.59-1.06]; P = 0.11), but there was with CV mortality (aHR: 0.53 [95% CI: 0.32-0.87]; P = 0.012). GLP-1RA-associated risk reduction in CV death was more pronounced in patients with a BMI >30 kg/m2 and appears to be greater in individuals with an ejection fraction ≤40% compared with >40%. This nationwide real-world study shows that patients with HF who received GLP-1RA have a significant reduction in CV mortality, which is particularly pronounced in overweight and obese patients with reduced ejection fraction.
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
Authors: Toru Kondo, Pardeep S Jhund, Inder S Anand, Brian L Claggett, Akshay S Desai, Kieran F Docherty, Carolyn S P Lam, Martin P Lefkowitz, Aldo P Maggioni, Felipe A Martinez, Margaret M Redfield, Jean L Rouleau, Dirk J Van Veldhuisen, Faiez Zannad, Michael R Zile, Milton Packer, Scott D Solomon, John J V McMurray
Journal: JACC Heart Failure (2025)

Recent trials of new heart failure (HF) treatments suggest the effect of therapy may vary by N-terminal pro-B type natriuretic peptide (NT-proBNP) level. The authors examined the efficacy of sacubitril/valsartan according to NT-proBNP levels in patients with reduced, mildly reduced, and preserved left ventricular ejection fraction (LVEF) enrolled in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) and PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction). Individual patient data from PARADIGM-HF and PARAGON-HF were pooled and participants were divided into categories defined by quintiles of NT-proBNP level. The primary outcome examined was the composite of HF hospitalization or cardiovascular death. Among the 13,195 patients enrolled in both trials, 13,142 (99.6%) had a baseline NT-proBNP level measured. The rate of the primary outcome (per 100 person-years) increased with NT-proBNP levels: quintile 1, 5.9 (95% CI: 5.3-6.5); quintile 2, 7.5 (95% CI: 6.9-8.2); quintile 3, 9.0 (95% CI: 8.2-9.7); quintile 4, 12.0 (95% CI: 11.1-12.9); and quintile 5, 20.8 (95% CI: 19.6-22.2). The relative risk reduction in the primary outcome with sacubitril/valsartan was consistent across NT-proBNP levels: the HR in quintile 1 was 0.79 (95% CI: 0.65-0.96); quintile 2, 0.87 (95% CI: 0.72-1.04); quintile 3, 0.79 (95% CI: 0.66-0.93); quintile 4, 0.85 (95% CI: 0.73-0.99); and quintile 5, 0.86 (95% CI: 0.76-0.97; P for interaction = 0.86). The absolute risk reduction was greatest in NT-proBNP quintile 5; the number needed to treat for the primary outcome over the median follow-up of 31 months was 16 in quintile 5 vs 37 in quintile 1. The relative risk reductions with sacubitril/valsartan were consistent irrespective of NT-proBNP level in HF patients across the range of LVEF. Consequently, the absolute risk reductions were greatest in patients with higher NT-proBNP levels. (PARADIGM-HF; NCT01035255; and PARAGON-HF; NCT01920711).
Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy
Authors: Masashi Amano, Hiroaki Kitaoka, Yusuke Yoshikawa, Yasushi Sakata, Kaoru Dohi, Yukichi Tokita, Takao Kato, Shouji Matsushima, Takeshi Kitai, Atsushi Okada, Yutaka Furukawa, Toshihiro Tamura, Akihiro Hayashida, Haruhiko Abe, Kenji Ando, Satoshi Yuda, Moriaki Inoko, Kazushige Kadota, Yukio Abe, Katsuomi Iwakura, Tetsuya Kitamura, Jun Masuda, Takahiro Ohara, Takashi Omura, Takashi Tanigawa, Kenji Nakamura, Kunihiro Nishimura, Chisato Izumi
Journal: JACC Heart Failure (2025)

To prevent sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM), the HCM Risk-SCD calculator and guideline recommendations are used to aid decision making for implantable cardioverter-defibrillator placement. The aim of this study was to assess the clinical profiles and occurrence of SCD by phenotypes of HCM and validate the performance of the current guidelines from a large-scale Japanese multicenter registry. This was a retrospective, multicenter, observational, longitudinal cohort study that enrolled 3,611 consecutive patients with HCM. The primary endpoint was a composite of SCD or an equivalent event. The 5-year cumulative incidence of SCD events was markedly high in patients with end-stage HCM, defined by ejection fraction <50% (18.5%), followed by midventricular obstruction and nonobstructive HCM (6.9% and 4.7%). The 5-year cumulative incidence rates of SCD events for each recommendation class by the 2 guidelines were as follows: with the 2024 ACC (American College of Cardiology)/AHA (American Heart Association) guidelines, 23.8%, 7.2%, 5.7%, and 2.3% for Classes 1, 2a, 2b, and 3, respectively, and with the 2023 ESC (European Society of Cardiology) guidelines, 23.8%, 2.9%, 9.3%, and 2.6%, respectively. The 5-year risk was not well stratified between Classes 2a and 2b with the 2024 ACC/AHA guidelines (P = 0.101), and the event rate was even reversed with the 2023 ESC guidelines (P = 0.545). Among HCM phenotypes, the prognosis of patients with end-stage HCM was markedly worse. The 2024 ACC/AHA and 2023 ESC guidelines well stratified SCD risk in patients with HCM; the 2024 ACC/AHA guidelines seemed to better stratify SCD risk between Classes 2a and 2b compared with the 2023 ESC guidelines.
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin
Authors: Kieran F Docherty, Kirsty McDowell, Paul Welsh, Mark C Petrie, Inder Anand, David D Berg, Rudolf A de Boer, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Eileen O'Meara, David A Morrow, Piotr Ponikowski, Marc S Sabatine, Naveed Sattar, Morten Schou, Ann Hammarstedt, Mikaela Sjöstrand, Anna Maria Langkilde, Pardeep S Jhund, Scott D Solomon, John J V McMurray
Journal: JACC Heart Failure (2025)

Inflammation may play an important pathophysiological role in the development and progression of heart failure (HF). Interleukin (IL)-6 is a circulating cytokine and is the main regulator of the release of C-reactive protein (CRP). The authors examined the association between IL-6 and high-sensitivity (hs)-CRP and outcomes in patients with HFrEF in the DAPA-HF trial and their relationship with the effect of dapagliflozin. Inclusion criteria included: 1) NYHA functional class II-IV; 2) left ventricular ejection fraction ≤40%; 3) elevated N-terminal pro-B-type natriuretic peptide; and 4) estimated glomerular filtration rate ≥30 mL/min/1.73 m2. The primary outcome was a composite of a worsening HF event or cardiovascular death. IL-6 and hs-CRP were measured at baseline and 12 months (Roche Diagnostics). The associations between IL-6 and hs-CRP and outcomes were adjusted for known prognostic variables, including NT-proBNP. Among 2,940 patients, median IL-6 and hs-CRP at baseline were 6.01 pg/mL (Q1-Q3: 4.18-9.28 pg/mL) and 2.05 mg/L (Q1-Q3: 0.83-4.9 mg/L), respectively. Baseline IL-6 tertiles (T) were: T1 ≤4.72 pg/mL; T2 4.73-7.89 pg/mL; and T3 ≥7.90 pg/mL. The adjusted risks of the primary outcome relative to T1 were as follows: T2 = HR 1.34 (95% CI: 1.04-1.73) and T3 = HR 1.80 (95% CI: 1.41-2.31). A rise in IL-6 between baseline and 12 months was associated with worse outcomes. The beneficial effect of dapagliflozin on the primary outcome was consistent regardless of IL-6 concentration (continuous interaction P = 0.57), with similar results for hs-CRP. Dapagliflozin did not reduce IL-6 or hs-CRP at 12 months. In DAPA-HF, elevated IL-6 and hs-CRP levels were each associated with the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of adverse outcomes regardless of baseline IL-6 or hs-CRP. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).
Stroke in Heart Failure With Reduced Ejection Fraction
Authors: Guglielmo Gallone, Federica Savoca, Davide Miccoli, Michael Böhm, Gaetano Maria De Ferrari, Stephen S Gottlieb, Patrizio Lancellotti, JoAnn Lindenfeld, Clara Saldarriaga, Zainab Samad, John R Teerlink, Gianluigi Savarese, Enrico Ammirati
Journal: JACC Heart Failure (2025)
Integrative phenomics, metabolomics and genomics analysis provides new insights for deciphering the genetic basis of metabolism in polished rice
Authors: Hui Feng, Yufei Li, Guoxin Dai, Zhuang Yang, Jingyan Song, Bingjie Lu, Yuan Gao, Yongqi Chen, Jiawei Shi, Luis A. J. Mur, Lejun Yu, Jie Luo, Wanneng Yang
Journal: Genome biology (2025)

Metabolomics is one of the most widely used omics tools for deciphering the functional networks of the metabolites for crop improvement. However, it is technically demanding and costly. We propose a relatively inexpensive approach for metabolomics analysis in which metabolomics is combined with hyperspectral imaging via machine learning. This approach can be used to target important steps in flavonoid and lipid biosynthesis in rice. We extract 1848 hyperspectral indices and 887 metabolites from polished grains of 533 Oryza sativa accessions. Hyperspectral indices are then linked to metabolites through correlation analysis and modelling. Based on this, a total of 554 metabolites and 1313 hyperspectral indices are identified for further genome-wide association study (GWAS). By GWAS, we detect 17,509 significant locus-trait associations with 2882 single nucleotide polymorphisms (SNPs). Colocalization analysis links these SNPs to the corresponding metabolites and hyperspectral indices. We detect 6415 pairs of metabolites and hyperspectral indices within a linkage disequilibrium of 300 kb in the Oryza sativa genome. We then characterize 1761 candidate genes colocalized to these loci by transcriptomic analysis. We further verify novel candidate genes encoding a novel flavonoid (LOC_Os09g18450) and a flavonoid/lipid (LOC_Os07g11020) respectively by gene editing and overexpression in rice. Our findings indicate that hyperspectral imaging combined with machine learning methods could serve as a powerful tool for quickly and inexpensively assessing crop metabolites.
Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation
Authors: Ling Lin, Zaixiang Fang, Guohao Liu, Yiwei Liu, Zhiqian Li, Dayi Pan, Yunkun Li, Hemi Kang, Xiaoding Shen, Jinyao Zhang, Qiyong Gong, Kui Luo, Jing Jing
Journal: Acta Pharmaceutica Sinica B (2025)
GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism
Authors: Fushun Kou, Xiao-Yu Li, Zhongsheng Feng, Jinghan Hua, Xiaohan Wu, Han Gao, Jian Lin, Dengfeng Kang, Ai Li, Junxiang Li, Yao Ding, Ting Ban, Qing Zhang, Zhanju Liu
Journal: Gut (2025)

Background GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear. Objective We aimed to investigate the role of GPR171 in modulating CD4 + T cell effector functions in IBD and evaluate its therapeutic potential. Design We analysed GPR171 expression in colon biopsies and peripheral blood samples from patients with IBD and assessed the impact of GPR171 on CD4 + T cell differentiation through administration of its endogenous ligand (BigLEN). We further determined the role of GPR171 in dextran sulfate sodium (DSS)-induced colitis and CD45RB high CD4 + T-cell transfer colitis model and deciphered the underlying mechanisms using RNA sequencing (RNA-seq) and lipidomics. We developed a novel BigLEN-based Fc fusion protein (BigLEN-Fc) and evaluated its potential in preventing and treating colitis. Results GPR171 was markedly increased in inflamed mucosa and CD4 + T cells of patients with IBD compared with controls. BigLEN-triggered GPR171 activation inhibited Th17 cell differentiation in vitro. GPR171 deficiency exacerbated DSS- and CD45RB high CD4 + T cell-induced colitis in mice, characterised by increased Th17 cell responses in intestinal mucosa. Mechanistically, GPR171 deficiency promoted Th17 cell differentiation and altered lipidome profile in Th17 cells via the cAMP-pCREB-FABP5 axis. Blockage of FABP5 reduced Th17 cell differentiation in vitro and ameliorated DSS-induced colitis in Gpr171 −/− mice. Furthermore, BigLEN-mutFc administration potently mitigated colitis in mice. Conclusions GPR171 deficiency promotes Th17 cell differentiation and causes lipid metabolism perturbation, contributing to intestinal inflammation in a FABP5-dependent manner. Target therapy (eg, BigLEN-Fc) represents a novel therapeutic approach for IBD treatment.
Quantifying Environmental Waste From Diabetes Devices in the U.S.
Authors: Tiffany Tian, Cindy N. Ho, Alessandra T. Ayers, Rachel E. Aaron, David C. Klonoff, David T. Ahn, David Kerr, Anne L. Peters, Athena Philis-Tsimikas, Viral N. Shah, Emily G. Herndon, Yijiong Yang, Chengdong Li, Jing Wang
Journal: Diabetes Care (2025)

OBJECTIVE Diabetes devices, including continuous glucose monitors (CGMs) and insulin pumps, may significantly affect environmental sustainability and long-term resilience. RESEARCH DESIGN AND METHODS This observational study enrolled 49 adults with diabetes using CGMs, insulin pumps, or multiple daily injections (MDIs; three or more per day). Participants completed daily surveys detailing the types and amounts of diabetes-related waste discarded. RESULTS Of the 49 participants, 11 used MDIs and 38 used insulin pumps. Most were female (63%), were White (80%), had a bachelor’s degree (90%), lived in suburban/urban areas (86%), and were aged &amp;lt;65 years (78%). Average monthly waste was 2.7 lbs for pumps and 3.1 lbs for MDIs. Diabetes-related products contributed nearly 2% of household waste. CONCLUSIONS This study highlights the importance of improving recycling methods and reducing waste from diabetes devices.